Ieq Capital LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 2nd quarter, HoldingsChannel reports. The firm acquired 33,739 shares of the biopharmaceutical company’s stock, valued at approximately $4,263,000.
Other hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC boosted its holdings in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter worth about $215,000. Sivia Capital Partners LLC boosted its stake in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares in the last quarter. Diversify Advisory Services LLC increased its position in shares of Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 674 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in Gilead Sciences by 1.6% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 541,512 shares of the biopharmaceutical company’s stock worth $60,037,000 after buying an additional 8,272 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Trading Up 0.4%
Gilead Sciences stock opened at $146.74 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The business’s fifty day simple moving average is $132.42 and its two-hundred day simple moving average is $136.57. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The company has a market capitalization of $181.95 billion, a price-to-earnings ratio of -54.96 and a beta of 0.32.
Gilead Sciences Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.
Insider Activity
In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the completion of the transaction, the chief financial officer directly owned 165,646 shares in the company, valued at $22,918,780.56. The trade was a 1.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,000 shares of company stock valued at $11,562,960 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Several analysts have weighed in on the company. Truist Financial cut their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Morgan Stanley decreased their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a report on Wednesday, May 20th. Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Finally, Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Twenty-four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $158.04.
View Our Latest Stock Analysis on Gilead Sciences
Gilead Sciences Company Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
